{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:09:08Z","timestamp":1781104148427,"version":"3.54.1"},"reference-count":142,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["RRCT"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Gout, an inflammatory arthritis form, is renowned for its historical association with affluence.\nThis review delves into its pathophysiology, exploring hyperuricemia, urate crystal formation,\nand the ensuing inflammatory response. The epidemiology of gout is examined, focusing on\nits rising prevalence and impact on public health. In this study, progress in gout management is\ndiscussed, involving pharmacological interventions, dietary changes, and emerging therapies. Genetic\npredisposition and triggers like alcohol, temperature, and diet are highlighted in this study.\nPrevention strategies, including serum urate-lowering therapy and lifestyle modifications, aim to\nreduce recurrent flares and complications. The inflammatory response in acute gout attacks is elucidated,\ninvolving immune cells, cytokines, and the NLRP3 inflammasome. Chronic gout manifestations,\nsuch as gouty tophus formation, are explored for their destructive impact on surrounding\ntissues. Recent advancements in gout treatment, including nanotherapies and novel compounds,\nare discussed, along with promising urate-lowering drugs. Cutting-edge research on zinc ferrite\nnanoparticles, dimethyl fumarate, and myricetin\/nobiletin hybrids addresses oxidative stress and\ninflammation in gout. Additionally, the potential therapeutic role of methanolic leaf extract of Euphorbia\nmilii and tip-loaded CLC-Soluplus\u00ae MAPs is explored as natural and transdermal alternatives\nfor gout management. The review also covers the development status of new urate-lowering\ndrugs, providing insights into promising candidates and their mechanisms. Patents on gout and recent\ndiagnostic advancements using techniques like laser confocal micro Raman spectrometer,\nFTIR, and THz-TDS offer a more accurate approach for gout stone analysis, enabling early detection\nand targeted treatment.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0115748871308473240926044126","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T11:40:21Z","timestamp":1728906021000},"page":"96-112","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["From Patents to Progress: Unraveling Gout's Journey Through Clinical Trials and Advancements"],"prefix":"10.2174","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4748-7229","authenticated-orcid":true,"given":"Vikash Singh","family":"Bhadouria","sequence":"first","affiliation":[{"name":"Department of Pharmaceutics, Noida Institute of Engineering and Technology (Pharmacy Institute), Greater Noida,\n201306, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7816-4625","authenticated-orcid":true,"given":"Sushma","family":"Verma","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Noida Institute of Engineering and Technology (Pharmacy Institute), Greater Noida,\n201306, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1227-619X","authenticated-orcid":true,"given":"Chhaya","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Noida Institute of Engineering and Technology, Greater Noida, 201306,\nIndia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2262-1476","authenticated-orcid":true,"given":"Deep Shikha","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Lovely Professional University, Phagwara, Punjab, 144001, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41572-019-0115-y","volume":"5","author":"Dalbeth N.","year":"2019","unstructured":"Dalbeth N.; Choi H.K.; Joosten L.A.B.; Khanna P.P.; Matsuo H.; Perez-Ruiz F.; Stamp L.K.; Gout. Nat Rev Dis Primers  2019,5(1),69","journal-title":"Nat Rev Dis Primers"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41584-018-0004-x","volume":"14","author":"Major T.J.","year":"2018","unstructured":"Major T.J.; Dalbeth N.; Stahl E.A.; Merriman T.R.; An update on the genetics of hyperuricaemia and gout. Nat Rev Rheumatol  2018,14(6),341-353","journal-title":"Nat Rev Rheumatol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1056\/NEJM199602153340707","volume":"334","author":"Emmerson B.T.","year":"1996","unstructured":"Emmerson B.T.; The management of gout. N Engl J Med  1996,334(7),445-451","journal-title":"N Engl J Med"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jare.2017.04.008","volume":"8","author":"Ragab G.","year":"2017","unstructured":"Ragab G.; Elshahaly M.; Bardin T.; Gout: An old disease in new perspective \u2013 A review. J Adv Res  2017,8(5),495-511","journal-title":"J Adv Res"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1136\/ard.2006.060368","volume":"66","author":"Pascual E.","year":"2007","unstructured":"Pascual E.; Sivera F.; Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Ann Rheum Dis  2007,66(8),1056-1058","journal-title":"Ann Rheum Dis"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/RHU.0000000000000091","volume":"20","author":"Singh J.A.","year":"2014","unstructured":"Singh J.A.; Challenges faced by patients in gout treatment: a qualitative study. J Clin Rheumatol  2014,20(3),172-174","journal-title":"J Clin Rheumatol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/j.semarthrit.2020.04.008","volume":"50","author":"Singh JA","year":"2020","unstructured":"Singh JA; Gaffo A; Gout epidemiology and comorbidities. Sem Arthr Rheumat  2020,50(3)(Suppl.),S11-S16","journal-title":"Sem Arthr Rheumat"},{"key":"ref=8","first-page":"240","volume":"49","author":"Chopra A.","year":"2001","unstructured":"Chopra A.; Patil J.; Billempelly V.; Relwani J.; Tandle H.S.; Prevalence of rheumatic diseases in a rural population in western India: a WHO-ILAR COPCORD Study. J Assoc Physicians India  2001,49,240-246","journal-title":"J Assoc Physicians India"},{"key":"ref=9","first-page":"12","volume":"13","author":"Matthew A.","year":"2004","unstructured":"Matthew A.; Danda D.; Clinical profile of young onset gout in India. J Ind Rheum Assoc  2004,13,12-18","journal-title":"J Ind Rheum Assoc"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"s9","DOI":"10.1210\/jc.2008-1595","volume":"93","author":"Misra A.","year":"2008","unstructured":"Misra A.; Khurana L.; Obesity and the metabolic syndrome in developing countries. J Clin Endocrinol Metab  2008,93(11_supplement_1)(Suppl. 1),s9-s30","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"166","DOI":"10.4103\/japtr.japtr_144_23","volume":"14","author":"Saleh M.I.","year":"2023","unstructured":"Saleh M.I.; Parisa N.; Kamaluddin M.T.; Sinaga E.; The inflammation process of gout arthritis and its treatment. J Adv Pharm Technol Res  2023,14(3),166-170","journal-title":"J Adv Pharm Technol Res"},{"key":"ref=12","first-page":"88","volume":"6","author":"Ahmed S.","year":"2018","unstructured":"Ahmed S.; Shaffique S.; Asif H.M.; Hussain G.; Ahmad K.; Pathophysiology, clinical consequences, epidemiology and treatment of hyperurecemic gout. RADS JPharm Pharmaceut Sci  2018,6(1),88-94","journal-title":"RADS JPharm Pharmaceut Sci"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1002\/art.10792","volume":"47","author":"Perez-Ruiz F.","year":"2002","unstructured":"Perez-Ruiz F.; Calabozo M.; Erauskin G.G.; Ruibal A.; Herrero-Beites A.M.; Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. Arthritis Care Res  2002,47(6),610-613","journal-title":"Arthritis Care Res"},{"key":"ref=14","first-page":"132","volume":"147","author":"Marangella M.","year":"2005","unstructured":"Marangella M.; Uric acid elimination in the urine. Pathophysiological implications. Contrib Nephrol  2005,147,132-148","journal-title":"Contrib Nephrol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1038\/s41440-023-01273-3","volume":"46","author":"Kuwabara M.","year":"2023","unstructured":"Kuwabara M.; Kodama T.; Ae R.; Kanbay M.; Andres-Hernando A.; Borghi C.; Hisatome I.; Lanaspa M.A.; Update in uric acid, hypertension, and cardiovascular diseases. Hypertens Res  2023,46(7),1714-1726","journal-title":"Hypertens Res"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s11926-016-0587-7","volume":"18","author":"Hyndman D.","year":"2016","unstructured":"Hyndman D.; Liu S.; Miner J.N.; Urate handling in the human body. Curr Rheumatol Rep  2016,18(6),34","journal-title":"Curr Rheumatol Rep"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1007\/s11926-013-0400-9","volume":"16","author":"Martillo M.A.","year":"2014","unstructured":"Martillo M.A.; Nazzal L.; Crittenden D.B.; The crystallization of monosodium urate. Curr Rheumatol Rep  2014,16(2),400","journal-title":"Curr Rheumatol Rep"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"e13937","DOI":"10.1111\/eci.13937","volume":"53","author":"Jeong Y.J.","year":"2023","unstructured":"Jeong Y.J.; Park S.; Yon D.K.; Lee S.W.; Tizaoui K.; Koyanagi A.; Jacob L.; Kostev K.; Dragioti E.; Radua J.; Stickley A.; Oh H.; Shin J.I.; Smith L.; Global burden of gout in 1990\u20132019: A systematic analysis of the Global Burden of Disease study 2019. Eur J Clin Invest  2023,53(4),e13937","journal-title":"Eur J Clin Invest"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nature04516","volume":"440","author":"Martinon F.","year":"2006","unstructured":"Martinon F.; P\u00e9trilli V.; Mayor A.; Tardivel A.; Tschopp J.; Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature  2006,440(7081),237-241","journal-title":"Nature"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1002\/art.1780390718","volume":"39","author":"Liot\u00e9 F.","year":"1996","unstructured":"Liot\u00e9 F.; Prudhommeaux F.; Schiltz C.; Champy R.; Herbelin A.; Ortiz-Bravo E.; Bardin T.; Inhibition and prevention of monosodium urate monohydrate crystal\u2013induced acute inflammation in vivo by transforming growth factor \u03b21. Arthritis Rheum  1996,39(7),1192-1198","journal-title":"Arthritis Rheum"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1002\/art.20317","volume":"50","author":"Yagnik D.R.","year":"2004","unstructured":"Yagnik D.R.; Evans B.J.; Florey O.; Mason J.C.; Landis R.C.; Haskard D.O.; Macrophage release of transforming growth factor \u03b21 during resolution of monosodium urate monohydrate crystal\u2013induced inflammation. Arthritis Rheum  2004,50(7),2273-2280","journal-title":"Arthritis Rheum"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1146\/annurev.immunol.021908.132715","volume":"27","author":"Martinon F.","year":"2009","unstructured":"Martinon F.; Mayor A.; Tschopp J.; The inflammasomes: guardians of the body. Annu Rev Immunol  2009,27(1),229-265","journal-title":"Annu Rev Immunol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1146\/annurev.immunol.021908.132612","volume":"27","author":"Dinarello C.A.","year":"2009","unstructured":"Dinarello C.A.; Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol  2009,27(1),519-550","journal-title":"Annu Rev Immunol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"4483","DOI":"10.1038\/s41598-022-08311-z","volume":"12","author":"Wessig A.K.","year":"2022","unstructured":"Wessig A.K.; Hoffmeister L.; Klingberg A.; Alberts A.; Pich A.; Brand K.; Witte T.; Neumann K.; Natural antibodies and CRP drive anaphylatoxin production by urate crystals. Sci Rep  2022,12(1),4483","journal-title":"Sci Rep"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/imr.12833","volume":"294","author":"Cab\u0103u G.","year":"2020","unstructured":"Cab\u0103u G.; Cri\u0219an T.O.; Kl\u00fcck V.; Popp R.A.; Joosten L.A.B.; Urate\u2010induced immune programming: Consequences for gouty arthritis and hyperuricemia. Immunol Rev  2020,294(1),92-105","journal-title":"Immunol Rev"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/cbf.3598","volume":"39","author":"Cao Y.","year":"2021","unstructured":"Cao Y.; Icariin alleviates -induced rat  models through \/ pathway. Cell Biochem Funct  2021,39(3),357-366","journal-title":"Cell Biochem Funct"},{"key":"ref=27","author":"Riley M","year":"2023","unstructured":"Riley M; Leong M.;  A Case-Based Approach to Knee Pain, A Pocket Guide to Pathology, Diagnosis and Management  2023","journal-title":"A Case-Based Approach to Knee Pain, A Pocket Guide to Pathology, Diagnosis and Management"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"7840","DOI":"10.3390\/ijms23147840","volume":"23","author":"Mikhalchik E.V.","year":"2022","unstructured":"Mikhalchik E.V.; Ivanov V.A.; Borodina I.V.; Pobeguts O.V.; Smirnov I.P.; Gorudko I.V.; Grigorieva D.V.; Boychenko O.P.; Moskalets A.P.; Klinov D.V.; Panasenko O.M.; Filatova L.Y.; Kirzhanova E.A.; Balabushevich N.G.; Neutrophil activation by mineral microparticles coated with methylglyoxal-glycated albumin. Int J Mol Sci  2022,23(14),7840","journal-title":"Int J Mol Sci"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1007\/s00296-020-04659-5","volume":"40","author":"Daoussis D.","year":"2020","unstructured":"Daoussis D.; Bogdanos D.P.; Dimitroulas T.; Sakkas L.; Andonopoulos A.P.; Adrenocorticotropic hormone: an effective \u201cnatural\u201d biologic therapy for acute gout? Rheumatol Int  2020,40(12),1941-1947","journal-title":"Rheumatol Int"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s00296-022-05128-x","volume":"42","author":"Daoussis D.","year":"2022","unstructured":"Daoussis D.; Kordas P.; Varelas G.; Michalaki M.; Onoufriou A.; Mamali I.; Iliopoulos G.; Melissaropoulos K.; Ntelis K.; Velissaris D.; Tzimas G.; Georgiou P.; Vamvakopoulou S.; Paliogianni F.; Andonopoulos A.P.; Georgopoulos N.; ACTH vs steroids for the treatment of acute gout in hospitalized patients: a randomized, open label, comparative study. Rheumatol Int  2022,42(6),949-958","journal-title":"Rheumatol Int"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"113868","DOI":"10.1016\/j.fct.2023.113868","volume":"178","author":"Soliman E.","year":"2023","unstructured":"Soliman E.; Elshazly S.M.; Shewaikh S.M.; El-shaarawy F.; Reno- and hepato-protective effect of allopurinol after renal ischemia\/reperfusion injury: Crosstalk between xanthine oxidase and peroxisome proliferator-activated receptor gamma signaling. Food Chem Toxicol  2023,178,113868","journal-title":"Food Chem Toxicol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"888306","DOI":"10.3389\/fimmu.2022.888306","volume":"13","author":"Zhao J.","year":"2022","unstructured":"Zhao J.; Wei K.; Jiang P.; Chang C.; Xu L.; Xu L.; Shi Y.; Guo S.; Xue Y.; He D.; Inflammatory response to regulated cell death in gout and its functional implications. Front Immunol  2022,13,888306","journal-title":"Front Immunol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41420-020-0255-6","volume":"6","author":"Brostjan C.","year":"2020","unstructured":"Brostjan C.; Oehler R.; The role of neutrophil death in chronic inflammation and cancer. Cell Death Discov  2020,6(1),26","journal-title":"Cell Death Discov"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s004280000282","volume":"437","author":"Schweyer S.","year":"2000","unstructured":"Schweyer S.; Hemmerlein B.; Radzun H.J.; Fayyazi A.; Continuous recruitment, co-expression of tumour necrosis factor-\u03b1 and matrix metalloproteinases, and apoptosis of macrophages in gout tophi. Virchows Arch  2000,437(5),534-539","journal-title":"Virchows Arch"},{"key":"ref=35","first-page":"243","volume":"94","author":"Hasselbacher P.","year":"1981","unstructured":"Hasselbacher P.; McMillan R.M.; Vater C.A.; Hahn J.; Harris E.D.; Stimulation of secretion of collagenase and prostaglandin E2 by synovial fibroblasts in response to crystals of monosodium urate monohydrate: a model for joint destruction in gout. Trans Assoc Am Physicians  1981,94,243-252","journal-title":"Trans Assoc Am Physicians"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.3390\/life13081690","volume":"13","author":"Gutowski \u0141.","year":"2023","unstructured":"Gutowski \u0141.; Kanikowski S.; Formanowicz D.; Mast cell involvement in the pathogenesis of selected musculoskeletal diseases. Life (Basel)  2023,13(8),1690","journal-title":"Life (Basel)"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"7129","DOI":"10.1080\/10408398.2021.1911928","volume":"62","author":"Nieradko-Iwanicka B.","year":"2022","unstructured":"Nieradko-Iwanicka B.; The role of alcohol consumption in pathogenesis of gout. Crit Rev Food Sci Nutr  2022,62(25),7129-7137","journal-title":"Crit Rev Food Sci Nutr"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"138155","DOI":"10.1016\/j.cej.2022.138155","volume":"450","author":"Meng Y.","year":"2022","unstructured":"Meng Y.; Qi Z.; Jiang H.; Li Z.; Xiao Q.; Xia Z.; Yu M.; Ruan X.; He G.; Jiang X.; Restrained MSUM crystallization via hydrogel composited membrane based platform for gout prevention and control. Chem Eng J  2022,450,138155","journal-title":"Chem Eng J"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.1021\/acs.cgd.9b01518","volume":"20","author":"Liu Y.","year":"2020","unstructured":"Liu Y.; Cheng R.; Ou C.; Zhang X.; Fu T.; Acetate: an alcohol metabolite as a growth promoter of pathological crystallization of gout. Cryst Growth Des  2020,20(5),2842-2846","journal-title":"Cryst Growth Des"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13075-021-02497-9","volume":"23","author":"Liu Y.R.","year":"2021","unstructured":"Liu Y.R.; Tantoh D.M.; Lin C.C.; Hsiao C.H.; Liaw Y.P.; Risk of gout among Taiwanese adults with ALDH-2 rs671 polymorphism according to BMI and alcohol intake. Arthritis Res Ther  2021,23(1),115","journal-title":"Arthritis Res Ther"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.3390\/cells10081919","volume":"10","author":"Ahn H.","year":"2021","unstructured":"Ahn H.; Lee G.; Lee G.S.; Lower temperatures exacerbate NLRP3 inflammasome activation by promoting monosodium urate crystallization, causing gout. Cells  2021,10(8),1919","journal-title":"Cells"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"637415","DOI":"10.3389\/fphar.2021.637415","volume":"12","author":"Zhang Q.B.","year":"2021","unstructured":"Zhang Q.B.; Zhu D.; Dai F.; Huang Y.Q.; Zheng J.X.; Tang Y.P.; Dong Z.R.; Liao X.; Qing Y.F.; MicroRNA-223 suppresses IL-1\u03b2 and TNF-\u03b1 production in gouty inflammation by targeting the NLRP3 inflammasome. Front Pharmacol  2021,12,637415","journal-title":"Front Pharmacol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"13797","DOI":"10.1007\/s11356-021-16580-w","volume":"29","author":"He Y.S.","year":"2022","unstructured":"He Y.S.; Wang G.H.; Wu Z.D.; Sam N.B.; Chen Y.; Tao J.H.; Fang X.Y.; Xu Z.; Pan H.F.; Association between non-optimal temperature and hospitalizations for gout in Anqing, China: a time-series analysis. Environ Sci Pollut Res Int  2022,29(10),13797-13804","journal-title":"Environ Sci Pollut Res Int"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"101723","DOI":"10.1016\/j.berh.2021.101723","volume":"35","author":"Danve A.","year":"2021","unstructured":"Danve A.; Sehra S.T.; Neogi T.; Role of diet in hyperuricemia and gout. Best Pract Res Clin Rheumatol  2021,35(4),101723","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"564","DOI":"10.3390\/antiox10040564","volume":"10","author":"Chang Y.H.","year":"2021","unstructured":"Chang Y.H.; Chiang Y.F.; Chen H.Y.; Huang Y.J.; Wang K.L.; Hong Y.H.; Ali M.; Shieh T.M.; Hsia S.M.; Anti-inflammatory and anti-hyperuricemic effects of chrysin on a high fructose corn syrup-induced hyperuricemia rat model via the amelioration of urate transporters and inhibition of NLRP3 inflammasome signaling pathway. Antioxidants  2021,10(4),564","journal-title":"Antioxidants"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.3390\/ijms21062147","volume":"21","author":"Hong F.","year":"2020","unstructured":"Hong F.; Zheng A.; Xu P.; Wang J.; Xue T.; Dai S.; Pan S.; Guo Y.; Xie X.; Li L.; Qiao X.; Liu G.; Zhai Y.; High-protein diet induces hyperuricemia in a new animal model for studying human gout. Int J Mol Sci  2020,21(6),2147","journal-title":"Int J Mol Sci"},{"key":"ref=47","first-page":"2131","volume":"10","author":"Bereda G.","year":"2021","unstructured":"Bereda G.; Antihypertensive medications: Explanation, mechanisms of action, adverse drug reaction, and drug interaction. Int J Chem Lifesci  2021,10(5),2131-2144","journal-title":"Int J Chem Lifesci"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"100065","DOI":"10.1016\/j.acpath.2022.100065","volume":"10","author":"Light J.","year":"2023","unstructured":"Light J.; Wellman L.L.; Conran R.M.; Educational Case: Gout. Acad Pathol  2023,10(1),100065","journal-title":"Acad Pathol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1002\/art.42381","volume":"75","author":"Eun Y.","year":"2023","unstructured":"Eun Y.; Han K.; Lee S.W.; Kim K.; Kang S.; Lee S.; Cha H.S.; Koh E.M.; Kim H.; Lee J.; Altered risk of incident gout according to Changes in metabolic syndrome Status: A nationwide, population-based cohort study of 1.29 million young men. Arthritis Rheumatol  2023,75(5),806-815","journal-title":"Arthritis Rheumatol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1010391","DOI":"10.3389\/fmed.2022.1010391","volume":"9","author":"Eun Y.","year":"2022","unstructured":"Eun Y.; Han K.; Lee S.W.; Kim K.; Kang S.; Lee S.; Cha H.S.; Koh E.M.; Kim H.; Lee J.; Increased risk of incident gout in young men with metabolic syndrome: A nationwide population-based cohort study of 3.5 million men. Front Med (Lausanne)  2022,9,1010391","journal-title":"Front Med (Lausanne)"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/BOR.0b013e3283438e13","volume":"23","author":"Singh J.A.","year":"2011","unstructured":"Singh J.A.; Reddy S.G.; Kundukulam J.; Risk factors for gout and prevention: a systematic review of the literature. Curr Opin Rheumatol  2011,23(2),192-202","journal-title":"Curr Opin Rheumatol"},{"key":"ref=52","first-page":"831","volume":"90","author":"Hainer B.L.","year":"2014","unstructured":"Hainer B.L.; Matheson E.; Wilkes R.T.; Diagnosis, treatment, and prevention of gout. Am Fam Physician  2014,90(12),831-836","journal-title":"Am Fam Physician"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11926-021-01020-y","volume":"23","author":"Yokose C.","year":"2021","unstructured":"Yokose C.; McCormick N.; Choi H.K.; Dietary and lifestyle-centered approach in gout care and prevention. Curr Rheumatol Rep  2021,23(7),51","journal-title":"Curr Rheumatol Rep"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"143","DOI":"10.11648\/j.ajhr.20210905.14","volume":"9","author":"Koguchi T.","year":"2021","unstructured":"Koguchi T.; Modification of dietary habits for prevention of gout in Japanese people: Gout and micronutrient intake or alcohol consumption. Am J Health Res  2021,9(5),143-157","journal-title":"Am J Health Res"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"CD010120","DOI":"10.1002\/14651858.CD010120.pub2","volume":"2021","author":"van Durme CM","year":"2021","unstructured":"van Durme CM; Wechalekar MD; Buchbinder R; Schlesinger N; van der Heijde D; Landew\u00e9 RB; Non-steroidal anti-inflammatory drugs for acute gout. Cochrane Database Syst Rev  2021,2021(12),CD010120","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1186\/ar1908","volume":"8","author":"Cronstein B.N.","year":"2006","unstructured":"Cronstein B.N.; Terkeltaub R.; The inflammatory process of gout and its treatment. Arthritis Res Ther  2006,8(Suppl 1)(Suppl. 1),S3","journal-title":"Arthritis Res Ther"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s10067-015-2991-1","volume":"35","author":"Zhang S.","year":"2016","unstructured":"Zhang S.; Zhang Y.; Liu P.; Zhang W.; Ma J.; Wang J.; Efficacy and safety of etoricoxib compared with NSAIDs in acute gout: a systematic review and a meta-analysis. Clin Rheumatol  2016,35(1),151-158","journal-title":"Clin Rheumatol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/j.clinthera.2014.07.017","volume":"36","author":"Dalbeth N.","year":"2014","unstructured":"Dalbeth N.; Lauterio T.J.; Wolfe H.R.; Mechanism of action of colchicine in the treatment of gout. Clin Ther  2014,36(10),1465-1479","journal-title":"Clin Ther"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"684","DOI":"10.2174\/1381612824999180115103951","volume":"24","author":"Pascart T.","year":"2018","unstructured":"Pascart T.; Richette P.; Colchicine in gout: an update. Curr Pharm Des  2018,24(6),684-689","journal-title":"Curr Pharm Des"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.ejim.2010.09.010","volume":"21","author":"Cocco G.","year":"2010","unstructured":"Cocco G.; Chu D.C.C.; Pandolfi S.; Colchicine in clinical medicine. A guide for internists. Eur J Intern Med  2010,21(6),503-508","journal-title":"Eur J Intern Med"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1016\/S0140-6736(08)60799-0","volume":"371","author":"Janssens H.J.E.M.","year":"2008","unstructured":"Janssens H.J.E.M.; Janssen M.; van de Lisdonk E.H.; van Riel P.L.C.M.; van Weel C.; Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet  2008,371(9627),1854-1860","journal-title":"Lancet"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s40266-017-0512-4","volume":"34","author":"Abhishek A.","year":"2017","unstructured":"Abhishek A.; Managing gout flares in the elderly: practical considerations. Drugs Aging  2017,34(12),873-880","journal-title":"Drugs Aging"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/13543776.2017.1261111","volume":"27","author":"Ojha R.","year":"2017","unstructured":"Ojha R.; Singh J.; Ojha A.; Singh H.; Sharma S.; Nepali K.; An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015). Expert Opin Ther Pat  2017,27(3),311-345","journal-title":"Expert Opin Ther Pat"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1038\/s41401-021-00800-7","volume":"43","author":"Chen M.","year":"2022","unstructured":"Chen M.; Meng L.; The double faced role of xanthine oxidoreductase in cancer. Acta Pharmacol Sin  2022,43(7),1623-1632","journal-title":"Acta Pharmacol Sin"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s11906-017-0793-3","volume":"19","author":"Bove M.","year":"2017","unstructured":"Bove M.; Cicero A.F.G.; Borghi C.; The effect of xanthine oxidase inhibitors on blood pressure and renal function. Curr Hypertens Rep  2017,19(12),95","journal-title":"Curr Hypertens Rep"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"102241","DOI":"10.1016\/j.coph.2022.102241","volume":"65","author":"Huddleston E.M.","year":"2022","unstructured":"Huddleston E.M.; Gaffo A.L.; Emerging strategies for treating gout. Curr Opin Pharmacol  2022,65,102241","journal-title":"Curr Opin Pharmacol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1080\/13696998.2020.1757456","volume":"23","author":"Pruis S.","year":"2020","unstructured":"Pruis S.; Jeon Y.K.; Pearce F.; Thong B.Y.H.; Aziz M.I.A.; Cost-effectiveness of sequential urate lowering therapies for the management of gout in Singapore. J Med Econ  2020,23(8),838-847","journal-title":"J Med Econ"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.abb.2019.01.031","volume":"670","author":"Szekanecz Z.","year":"2019","unstructured":"Szekanecz Z.; Szamosi S.; Kov\u00e1cs G.E.; Kocsis E.; Benk\u0151 S.; The NLRP3 inflammasome - interleukin 1 pathway as a therapeutic target in gout. Arch Biochem Biophys  2019,670,82-93","journal-title":"Arch Biochem Biophys"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"619273","DOI":"10.3389\/fphar.2020.619273","volume":"11","author":"Malcova H.","year":"2021","unstructured":"Malcova H.; Milota T.; Strizova Z.; Cebecauerova D.; Striz I.; Sediva A.; Horvath R.; Interleukin-1 blockade in polygenic autoinflammatory disorders: where are we now? Front Pharmacol  2021,11,619273","journal-title":"Front Pharmacol"},{"key":"ref=70","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.semarthrit.2020.04.011","volume":"50","author":"Schlesinger N","year":"2020","unstructured":"Schlesinger N; Lipsky PE; Pegloticase treatment of chronic refractory gout: Update on efficacy and safety. Semin Arthritis Rheum  2020,50(3S),S31-S38","journal-title":"Semin Arthritis Rheum"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11926-022-01055-9","volume":"24","author":"Botson J.K.","year":"2022","unstructured":"Botson J.K.; Baraf H.S.B.; Keenan R.T.; Albert J.; Masri K.R.; Peterson J.; Yung C.; Freyne B.; Amin M.; Abdellatif A.; Soloman N.; Edwards N.L.; Strand V.; Expert opinion on pegloticase with concomitant immunomodulatory therapy in the treatment of uncontrolled gout to improve efficacy, safety, and durability of response. Curr Rheumatol Rep  2022,24(1),12-19","journal-title":"Curr Rheumatol Rep"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.2139\/ssrn.4554185","author":"Zhang F.","unstructured":"Zhang F.; Gan Y.; Xie W.; Zha Y.; Liang Y.; Ge Y.; Zhang J.; Qian J.; Duan Y.; Wu Z.; Zhang S.; Role of novel zinc ferrite nanoparticle in gout arthritis: Alleviating inflammation and oxidative stress by regulating Nlrp3 inflammasome activation and Nrf2 pathway. SSRN  ,2022","journal-title":"SSRN"},{"key":"ref=73","first-page":"628","volume":"27","author":"Cao Y.","year":"2023","unstructured":"Cao Y.; Hu Y.; Jin X.F.; Liu Y.; Zou J.M.; Dimethyl fumarate attenuates MSU-induced gouty arthritis by inhibiting NLRP3 inflammasome activation and oxidative stress. Eur Rev Med Pharmacol Sci  2023,27(2),628-641","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"21448","DOI":"10.1039\/D3RA03188H","volume":"13","author":"Li Y.","year":"2023","unstructured":"Li Y.; Pu L.Y.; Li Y.; Zhu G.; Wu Z.; Design, synthesis and evaluation of a myricetin and nobiletin hybrid compound for alleviating hyperuricemia based on metabolomics and gut microbiota. RSC Advances  2023,13(31),21448-21458","journal-title":"RSC Advances"},{"key":"ref=75","first-page":"189","volume":"27","author":"Mutalib N.S.","year":"2023","unstructured":"Mutalib N.S.; Zain M.H.; Asari A.; Maulidiani M.; Aziz A.N.; Yusuf N.; Wahab N.H.; Malaysian medicinal plants (Euphorbia milii) as a drug alternative source for anti-gout therapy. Malays J Anal Sci  2023,27(1),189-197","journal-title":"Malays J Anal Sci"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"5838","DOI":"10.1039\/D2BM01068B","volume":"10","author":"Anjani Q.K.","year":"2022","unstructured":"Anjani Q.K.; Sabri A.H.B.; Moreno-Castellanos N.; Utomo E.; C\u00e1rcamo-Mart\u00ednez \u00c1.; Dom\u00ednguez-Robles J.; Wardoyo L.A.H.; Donnelly R.F.; Soluplus\u00ae-based dissolving microarray patches loaded with colchicine: Towards a minimally invasive treatment and management of gout. Biomater Sci  2022,10(20),5838-5855","journal-title":"Biomater Sci"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"101487","DOI":"10.1016\/j.jddst.2019.101487","volume":"55","author":"Chen Z.","year":"2020","unstructured":"Chen Z.; Han B.; Liao L.; Hu X.; Hu Q.; Gao Y.; Qiu Y.; Enhanced transdermal delivery of polydatin via a combination of inclusion complexes and dissolving microneedles for treatment of acute gout arthritis. J Drug Deliv Sci Technol  2020,55,101487","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ajps.2013.07.010","volume":"8","author":"Fan Y.","year":"2013","unstructured":"Fan Y.; Zhang Q.; Development of liposomal formulations: From concept to clinical investigations. Asian J Pharm Sci  2013,8(2),81-87","journal-title":"Asian J Pharm Sci"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"975","DOI":"10.2147\/IJN.S68861","volume":"10","author":"Bozzuto G.","year":"2015","unstructured":"Bozzuto G.; Molinari A.; Liposomes as nanomedical devices. Int J Nanomedicine  2015,10,975-999","journal-title":"Int J Nanomedicine"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/1556-276X-8-102","volume":"8","author":"Akbarzadeh A.","year":"2013","unstructured":"Akbarzadeh A.; Rezaei-Sadabady R.; Davaran S.; Joo S.W.; Zarghami N.; Hanifehpour Y.; Samiei M.; Kouhi M.; Nejati-Koshki K.; Liposome: Classification, preparation, and applications. Nanoscale Res Lett  2013,8(1),102","journal-title":"Nanoscale Res Lett"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1208\/s12248-008-9078-8","volume":"11","author":"Singh H.P.","year":"2009","unstructured":"Singh H.P.; Utreja P.; Tiwary A.K.; Jain S.; Elastic liposomal formulation for sustained delivery of colchicine: In vitro characterization and in vivo evaluation of anti-gout activity. AAPS J  2009,11(1),54-64","journal-title":"AAPS J"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.colsurfb.2015.02.037","volume":"128","author":"Pando D.","year":"2015","unstructured":"Pando D.; Matos M.; Guti\u00e9rrez G.; Pazos C.; Formulation of resveratrol entrapped niosomes for topical use. Colloids Surf B Biointerfaces  2015,128,398-404","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=83","first-page":"25","volume":"2","author":"Chandu V.P.","year":"2012","unstructured":"Chandu V.P.; Arunachalam A.; Jeganath S.; Yamini K.; Tharangini K.; Chaitanya G.; Niosomes: a novel drug delivery system. Int J Novel Trends Pharm Sci  2012,2(1),25-31","journal-title":"Int J Novel Trends Pharm Sci"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1080\/08982104.2016.1174943","volume":"27","author":"Singh N.","year":"2017","unstructured":"Singh N.; Parashar P.; Tripathi C.B.; Kanoujia J.; Kaithwas G.; Saraf S.A.; Oral delivery of allopurinol niosomes in treatment of gout in animal model. J Liposome Res  2017,27(2),130-138","journal-title":"J Liposome Res"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2174\/157016312799304552","volume":"9","author":"Parhi R.","year":"2012","unstructured":"Parhi R.; Suresh P.; Preparation and characterization of solid lipid nanoparticles-a review. Curr Drug Discov Technol  2012,9(1),2-16","journal-title":"Curr Drug Discov Technol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1002\/jps.23522","volume":"102","author":"Mosallaei N.","year":"2013","unstructured":"Mosallaei N.; Jaafari M.R.; Hanafi-Bojd M.Y.; Golmohammadzadeh S.; Malaekeh-Nikouei B.; Docetaxel-loaded solid lipid nanoparticles: preparation, characterization, in vitro, and in vivo evaluations. J Pharm Sci  2013,102(6),1994-2004","journal-title":"J Pharm Sci"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ijpharm.2012.03.027","volume":"430","author":"Wang S.","year":"2012","unstructured":"Wang S.; Chen T.; Chen R.; Hu Y.; Chen M.; Wang Y.; Emodin loaded solid lipid nanoparticles: Preparation, characterization and antitumor activity studies. Int J Pharm  2012,430(1-2),238-246","journal-title":"Int J Pharm"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ijpharm.2018.08.028","volume":"550","author":"Wang Q.","year":"2018","unstructured":"Wang Q.; Yang Q.; Cao X.; Wei Q.; Firempong C.K.; Guo M.; Shi F.; Xu X.; Deng W.; Yu J.; Enhanced oral bioavailability and anti-gout activity of [6]-shogaol-loaded solid lipid nanoparticles. Int J Pharm  2018,550(1-2),24-34","journal-title":"Int J Pharm"},{"key":"ref=89","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-814487-9.00009-0","author":"Rajpoot K","year":"2020","unstructured":"Rajpoot K; Tekade M; Pandey V; Nagaraja S; Youngren-Ortiz SR; Tekade RK;  Drug Delivery Systems: Advances in Pharmaceutical Product Development and Research  2020","journal-title":"Drug Delivery Systems: Advances in Pharmaceutical Product Development and Research"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1208\/s12249-014-0280-y","volume":"16","author":"Wu L.","year":"2015","unstructured":"Wu L.; Qiao Y.; Wang L.; Guo J.; Wang G.; He W.; Yin L.; Zhao J.; A self-microemulsifying drug delivery system (SMEDDS) for a novel medicative compound against depression: A preparation and bioavailability study in rats. AAPS PharmSciTech  2015,16(5),1051-1058","journal-title":"AAPS PharmSciTech"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ajps.2014.08.003","volume":"10","author":"Qureshi M.J.","year":"2015","unstructured":"Qureshi M.J.; Mallikarjun C.; Kian W.G.; Enhancement of solubility and therapeutic potential of poorly soluble lovastatin by SMEDDS formulation adsorbed on directly compressed spray dried magnesium aluminometasilicate liquid loadable tablets: A study in diet induced hyperlipidemic rabbits. Asian J Pharm Sci  2015,10(1),40-56","journal-title":"Asian J Pharm Sci"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1208\/s12249-019-1421-0","volume":"20","author":"Zhang K.","year":"2019","unstructured":"Zhang K.; Wang Q.; Yang Q.; Wei Q.; Man N.; Adu-Frimpong M.; Toreniyazov E.; Ji H.; Yu J.; Xu X.; Enhancement of oral bioavailability and anti-hyperuricemic activity of isoliquiritigenin via self-microemulsifying drug delivery system. AAPS PharmSciTech  2019,20(5),218","journal-title":"AAPS PharmSciTech"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1517\/17425247.3.6.727","volume":"3","author":"Benson H.A.E.","year":"2006","unstructured":"Benson H.A.E.; Transfersomes for transdermal drug delivery. Expert Opin Drug Deliv  2006,3(6),727-737","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.jsps.2012.02.001","volume":"20","author":"Malakar J.","year":"2012","unstructured":"Malakar J.; Sen S.O.; Nayak A.K.; Sen K.K.; Formulation, optimization and evaluation of transferosomal gel for transdermal insulin delivery. Saudi Pharm J  2012,20(4),355-363","journal-title":"Saudi Pharm J"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"404","DOI":"10.2174\/1574885515666200120124214","volume":"15","author":"Tiwari R.","year":"2020","unstructured":"Tiwari R.; Tiwari G.; Singh R.; Allopurinol loaded transferosomes for the alleviation of symptomatic after-effects of Gout: An Account of Pharmaceutical implications. Curr Drug Ther  2020,15(4),404-419","journal-title":"Curr Drug Ther"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00340-008-2933-6","volume":"90","author":"Manceau J.M.","year":"2008","unstructured":"Manceau J.M.; Nevin A.; Fotakis C.; Tzortzakis S.; Terahertz time domain spectroscopy for the analysis of cultural heritage related materials. Appl Phys B  2008,90(3-4),365-368","journal-title":"Appl Phys B"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1080\/05704928.2021.1946076","volume":"56","author":"Paraskevaidi M.","year":"2021","unstructured":"Paraskevaidi M.; Matthew B.J.; Holly B.J.; Hugh B.J.; Thulya C.P.V.; Loren C.; StJohn C.; Peter G.; Callum G.; Sergei K.G.; Kamila K.; Maria K.; K\u00e1ssio L.M.G.; Pierre M-H.L.; Evangelos P.; Savithri P.; John A.A.; Alexandra S.; Marfran S.; Josep S-S.; Gunjan T.; Michael W.; Bayden W.; Clinical applications of infrared and Raman spectroscopy in the fields of cancer and infectious diseases. Appl Spectrosc Rev  2021,56(8-10),804-868","journal-title":"Appl Spectrosc Rev"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s10555-018-9770-9","volume":"37","author":"Auner G.W.","year":"2018","unstructured":"Auner G.W.; Koya S.K.; Huang C.; Broadbent B.; Trexler M.; Auner Z.; Elias A.; Mehne K.C.; Brusatori M.A.; Applications of Raman spectroscopy in cancer diagnosis. Cancer Metastasis Rev  2018,37(4),691-717","journal-title":"Cancer Metastasis Rev"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1080\/05704920701551530","volume":"42","author":"Movasaghi Z.","year":"2007","unstructured":"Movasaghi Z.; Rehman S.; Rehman I.U.; Raman spectroscopy of biological tissues. Appl Spectrosc Rev  2007,42(5),493-541","journal-title":"Appl Spectrosc Rev"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jpba.2012.03.009","volume":"66","author":"Jamr\u00f3giewicz M.","year":"2012","unstructured":"Jamr\u00f3giewicz M.; Application of the near-infrared spectroscopy in the pharmaceutical technology. J Pharm Biomed Anal  2012,66,1-10","journal-title":"J Pharm Biomed Anal"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s00340-021-07732-4","volume":"128","author":"Castro-Camus E.","year":"2022","unstructured":"Castro-Camus E.; Koch M.; Mittleman D.M.; Recent advances in terahertz imaging: 1999 to 2021. Appl Phys B  2022,128(1),12","journal-title":"Appl Phys B"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.34067\/KID.0001672021","volume":"2","author":"Bakris G.L.","year":"2021","unstructured":"Bakris G.L.; Mikami H.; Hirata M.; Nakajima A.; Cressman M.D.; A non-purine xanthine oxidoreductase inhibitor reduces albuminuria in patients with DKD: A randomized controlled trial. Kidney360  2021,2(8),1240-1250","journal-title":"Kidney360"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"5033","DOI":"10.2147\/DDDT.S86884","volume":"9","author":"Yoon S.","year":"2015","unstructured":"Yoon S.; Lee H.; Jang I-J.; Yu K-S.; Shin D.; Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects. Drug Des Devel Ther  2015,9,5033-5049","journal-title":"Drug Des Devel Ther"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1517\/13543784.2015.1051617","volume":"24","author":"Shahid H.","year":"2015","unstructured":"Shahid H.; Singh J.A.; Investigational drugs for hyperuricemia. Expert Opin Investig Drugs  2015,24(8),1013-1030","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1002\/art.39684","volume":"68","author":"Poiley J.","year":"2016","unstructured":"Poiley J.; Steinberg A.S.; Choi Y.J.; Davis C.S.; Martin R.L.; McWherter C.A.; Boudes P.F.; A randomized, double-blind, active-and placebo-controlled efficacy and safety study of arhalofenate for reducing flare in patients with gout. Arthritis Rheumatol  2016,68(8),2027-2034","journal-title":"Arthritis Rheumatol"},{"key":"ref=106","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3899\/jrheum.161062","volume":"44","author":"Steinberg AS","year":"2017","unstructured":"Steinberg AS; Vince BD; Choi Y-J; Martin RL; McWherter CA; The pharmacodynamics, pharmacokinetics, and safety of arhalofenate in combination with febuxostat when treating hyperuricemia associated with gout. J Rheumatol  2017,44(3),374-379","journal-title":"J Rheumatol"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jsps.2021.12.009","volume":"30","author":"Abdel-Latif R.T.","year":"2022","unstructured":"Abdel-Latif R.T.; Wadie W.; Abdel-mottaleb Y.; Abdallah D.M.; El-Maraghy N.N.; El-Abhar H.S.; Reposition of the anti-inflammatory drug diacerein in an in-vivo colorectal cancer model. Saudi Pharm J  2022,30(1),72-90","journal-title":"Saudi Pharm J"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00210-016-1324-5","volume":"390","author":"Taniguchi T.","year":"2017","unstructured":"Taniguchi T.; Ashizawa N.; Matsumoto K.; Iwanaga T.; Enhancement of pharmacological effects of uricosuric agents by concomitant treatment with pyrazinamide in rats. Naunyn Schmiedebergs Arch Pharmacol  2017,390(3),253-260","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1124\/jpet.119.259341","volume":"371","author":"Taniguchi T.","year":"2019","unstructured":"Taniguchi T.; Ashizawa N.; Matsumoto K.; Saito R.; Motoki K.; Sakai M.; Chikamatsu N.; Hagihara C.; Hashiba M.; Iwanaga T.; Pharmacological evaluation of dotinurad, a selective urate reabsorption inhibitor. J Pharmacol Exp Ther  2019,371(1),162-170","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"5089","DOI":"10.1093\/rheumatology\/keab198","volume":"60","author":"Lin Y.","year":"2021","unstructured":"Lin Y.; Chen X.; Ding H.; Ye P.; Gu J.; Wang X.; Jiang Z.; Li D.; Wang Z.; Long W.; Li Z.; Jiang G.; Li X.; Bi L.; Jiang L.; Wu J.; Guo L.; Cai X.; Lu X.; Chen Q.; Chen H.; Peng A.; Zuo X.; Ning R.; Zhang Z.; Tai Y.; Zhang T.; Bao C.; Efficacy and safety of a selective URAT1 inhibitor SHR4640 in Chinese subjects with hyperuricaemia: a randomized controlled phase II study. Rheumatology (Oxford)  2021,60(11),5089-5097","journal-title":"Rheumatology (Oxford)"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s40256-020-00400-6","volume":"20","author":"Mouradjian M.T.","year":"2020","unstructured":"Mouradjian M.T.; Plazak M.E.; Gale S.E.; Noel Z.R.; Watson K.; Devabhakthuni S.; Pharmacologic management of gout in patients with cardiovascular disease and heart failure. Am J Cardiovasc Drugs  2020,20(5),431-445","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref=112","first-page":"127","volume":"79","author":"Zhang L","year":"2020","unstructured":"Zhang L; Wyatt D; Stazzone K; Shi Z; Wang Y.; OP0205\u2005phase i study of D-0120, a novel URAT1 inhibitor in clinical development for hyperuricemia and gout. BMJ  2020,79(1),127","journal-title":"BMJ"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41598-017-00706-7","volume":"7","author":"Tan P.K.","year":"2017","unstructured":"Tan P.K.; Liu S.; Gunic E.; Miner J.N.; Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout. Sci Rep  2017,7(1),665","journal-title":"Sci Rep"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1093\/rheumatology\/key100","volume":"57","author":"Shiramoto M.","year":"2018","unstructured":"Shiramoto M.; Liu S.; Shen Z.; Yan X.; Yamamoto A.; Gillen M.; Ito Y.; Hall J.; Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study. Rheumatology (Oxford)  2018,57(9),1602-1610","journal-title":"Rheumatology (Oxford)"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1080\/14397595.2018.1538003","volume":"29","author":"Fitz-Patrick D.","year":"2019","unstructured":"Fitz-Patrick D.; Roberson K.; Niwa K.; Fujimura T.; Mori K.; Hall J.; Yan X.; Shen Z.; Liu S.; Ito Y.; Baumgartner S.; Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and\/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials. Mod Rheumatol  2019,29(6),1042-1052","journal-title":"Mod Rheumatol"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"e000584","DOI":"10.1136\/rmdopen-2017-000584","volume":"4","author":"Fleischmann R.","year":"2018","unstructured":"Fleischmann R.; Winkle P.; Miner J.N.; Yan X.; Hicks L.; Valdez S.; Hall J.; Liu S.; Shen Z.; Gillen M.; Hernandez-Illas M.; Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study. RMD Open  2018,4(1),e000584","journal-title":"RMD Open"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"e000647","DOI":"10.1136\/rmdopen-2018-000647","volume":"4","author":"Fleischmann R.","year":"2018","unstructured":"Fleischmann R.; Winkle P.; Hall J.; Valdez S.; Liu S.; Yan X.; Hicks L.; Lee C.; Miner J.N.; Gillen M.; Hernandez-Illas M.; Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study. RMD Open  2018,4(1),e000647","journal-title":"RMD Open"},{"key":"ref=118","first-page":"1976","volume":"58","author":"Lee H.A.","year":"2019","unstructured":"Lee H.A.; Yu K.S.; Park S.I.; Yoon S.; Onohara M.; Ahn Y.; Lee H.; URC102, a potent and selective inhibitor of hURAT1, reduced serum uric acid in healthy volunteers. Rheumatology (Oxford)  2019,58(11),1976-1984","journal-title":"Rheumatology (Oxford)"},{"key":"ref=119","first-page":"759","volume":"66","author":"Ichida K.","year":"2008","unstructured":"Ichida K.; New antihyperuricemic medicine: Febuxostat, Puricase, etc. Jpn J Clin Med  2008,66(4),759-765","journal-title":"Jpn J Clin Med"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1080\/13543784.2018.1471133","volume":"27","author":"Pascart T.","year":"2018","unstructured":"Pascart T.; Richette P.; Investigational drugs for hyperuricemia, an update on recent developments. Expert Opin Investig Drugs  2018,27(5),437-444","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2217\/ijr.10.9","volume":"5","author":"Fay B.T.","year":"2010","unstructured":"Fay B.T.; Mikuls T.R.; Advances and unmet needs in gout. Int J Clin Rheumatol  2010,5(2),187-197","journal-title":"Int J Clin Rheumatol"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s40744-023-00546-0","volume":"10","author":"Kivitz A.","year":"2023","unstructured":"Kivitz A.; DeHaan W.; Azeem R.; Park J.; Rhodes S.; Inshaw J.; Leung S.S.; Nicolaou S.; Johnston L.; Kishimoto T.K.; Traber P.G.; Sands E.; Choi H.; Phase 2 dose-finding study in patients with gout using SEL-212, a novel PEGylated uricase (SEL-037) combined with tolerogenic nanoparticles (SEL-110). Rheumatol Ther  2023,10(4),825-847","journal-title":"Rheumatol Ther"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/14728214.2018.1527899","volume":"23","author":"Stamp L.K.","year":"2018","unstructured":"Stamp L.K.; Merriman T.R.; Singh J.A.; Expert opinion on emerging urate-lowering therapies. Expert Opin Emerg Drugs  2018,23(3),201-209","journal-title":"Expert Opin Emerg Drugs"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"137","DOI":"10.6032\/gnam.40.137","volume":"40","author":"Otsuka Y.","year":"2016","unstructured":"Otsuka Y.; Ohno Y.; Morita A.; Otani N.; Jutabha P.; Ouchi M.; Tsuruoka S.; Anzai N.; Molecular mechanism of urate-lowering effects of anserine nitrate. Gout Nucleic Acid Metabol  2016,40(2),137-143","journal-title":"Gout Nucleic Acid Metabol"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3892\/br.2016.701","volume":"5","author":"Kubomura D.","year":"2016","unstructured":"Kubomura D.; Yamada M.; Masui A.; Tuna extract reduces serum uric acid in gout-free subjects with insignificantly high serum uric acid: A randomized controlled trial. Biomed Rep  2016,5(2),254-258","journal-title":"Biomed Rep"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/hr.2014.75","volume":"37","author":"Kuwabara M.","year":"2014","unstructured":"Kuwabara M.; Niwa K.; Nishi Y.; Mizuno A.; Asano T.; Masuda K.; Komatsu I.; Yamazoe M.; Takahashi O.; Hisatome I.; Relationship between serum uric acid levels and hypertension among Japanese individuals not treated for hyperuricemia and hypertension. Hypertens Res  2014,37(8),785-789","journal-title":"Hypertens Res"},{"key":"ref=127","author":"Matsuo H.","year":"2021","unstructured":"Matsuo H.; Shinomiya N.; Takada T.; Inhibiting the onset of gout.  2021"},{"key":"ref=128","author":"Ranganathan N.","year":"2017","unstructured":"Ranganathan N.; Composition and method for preventing or treating gout or hyperuricemia. United States patent US.  2017"},{"key":"ref=129","author":"Quart B.D.","year":"2019","unstructured":"Quart B.D.; Girardet J.L.; Gunic E.; Yeh L.T.; Compounds and compositions and methods of use.  2019"},{"key":"ref=130","author":"Moloney A.P.","year":"2021","unstructured":"Moloney A.P.; Compositions and methods of use.  2021"},{"key":"ref=131","author":"Chen S.J.","year":"2017","unstructured":"Chen S.J.; Chen Y.L.; Hsu H.Y.; Wann S.Y.; Chen M.H.; Yu L.W.; Strain of Lactobacillus rhamnosus and its metabolites for use in inhibiting xanthine oxidase and treating gout.  2017"},{"key":"ref=132","author":"Hsieh P.S.","year":"2023","unstructured":"Hsieh P.S.; Hsieh-Hsun H.O.; Tsai Y.C.; Kuo C.W.; Method for reducing blood uric acid concentration and for degrading purine.  2023"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"6863","DOI":"10.1021\/acs.cgd.8b01083","volume":"18","author":"Terruzzi S.","year":"2018","unstructured":"Terruzzi S.; Bellomi S.; Marras G.; Barreca G.; Ventimiglia G.; Cervellino A.; Masciocchi N.; Disclosing the rich crystal chemistry of lesinurad by ab initio laboratory X-ray powder diffraction methods. Cryst Growth Des  2018,18(11),6863-6872","journal-title":"Cryst Growth Des"},{"key":"ref=134","author":"Ku MS","year":"2017","unstructured":"Ku MS; Chen CK; Lu WS; Lin IY; M\u00e9todos y composiciones para tratar hiperuricemia y trastornos metab\u00f3licos asociados con hiperuricemia.  2017"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"11616","DOI":"10.1021\/acs.chemrev.0c00416","volume":"120","author":"Agnew-Francis K.A.","year":"2020","unstructured":"Agnew-Francis K.A.; Williams C.M.; Squaramides as bioisosteres in contemporary drug design. Chem Rev  2020,120(20),11616-11650","journal-title":"Chem Rev"},{"key":"ref=136","author":"Davis M.W.","year":"2013","unstructured":"Davis M.W.; Feng H.; Colchine compositions and methods.  2013"},{"key":"ref=137","year":"2018","unstructured":"FDA Approves Galafold\u2122 (migalastat) for the Treatment of Certain Adult Patients with Fabry Disease. Amicus Therapeutics Available From:     https:\/\/ir.amicusrx.com\/news-releases\/news-release-details\/fda-approves-galafoldtm-migalastat-treatment-certain-adult2018"},{"key":"ref=138","author":"Zhang C.","year":"2015","unstructured":"Zhang C.; Fan K.; Ma X.; Yang L.; Hu C.; Luo H.; Mei X.; Pegylated analogue protein or canine urate oxidase, preparation method and use thereof.  2015"},{"key":"ref=139","author":"Chen C.","year":"2014","unstructured":"Chen C.; Lu J.M.; Yao Q.; Small molecule xanthine oxidase inhibitors and methods of use.  2014"},{"key":"ref=140","author":"Shi D.","year":"2020","unstructured":"Shi D.; Changjin F.U.; Cheng X.; Zhu J.; Gu J.; URAT1 inhibitor and use thereof.  2020"},{"key":"ref=141","author":"Fitzgerald K.","year":"2018","unstructured":"Fitzgerald K.; Hinkle G.; Mooney T.R.; Xanthine dehydrogenase (xdh) irna compositions and methods of use thereof.  2018"},{"key":"ref=142","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000012259","volume":"67","author":"Theorell  T.","year":"1998; Jan 12","unstructured":"Theorell T.; Konarski K.; Westerlund H.; Burell AM.; Engstr\u00f6m R.; Lagercrantz AM.; Teszary J.; Thulin K.; Treatment of patients with chronic somatic symptoms by means of art psychotherapy: A process description. Psychotherapy and Psychosomatics,  1998; Jan 12,67(1),50-56","journal-title":"Psychotherapy and Psychosomatics,"}],"container-title":["Reviews on Recent Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115748871308473240926044126","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/234916\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115748871308473240926044126","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T14:19:21Z","timestamp":1745245161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/234916\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":142,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115748871308473240926044126","relation":{},"ISSN":["1574-8871"],"issn-type":[{"value":"1574-8871","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-02-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}